Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Depreciation and Depletion (2024 - 2025)

Historic Depreciation and Depletion for Anika Therapeutics (ANIK) over the last 2 years, with Q3 2025 value amounting to $1.4 million.

  • Anika Therapeutics' Depreciation and Depletion rose 769.23% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 million, marking a year-over-year change of. This contributed to the annual value of $5.0 million for FY2024, which is 204.08% up from last year.
  • As of Q3 2025, Anika Therapeutics' Depreciation and Depletion stood at $1.4 million, which was up 769.23% from $1.3 million recorded in Q2 2025.
  • Anika Therapeutics' Depreciation and Depletion's 5-year high stood at $1.4 million during Q3 2025, with a 5-year trough of $1.2 million in Q1 2024.